Search Results - "Plager, C"

Phase II Clinical Investigation of Gemcitabine in Advanced Soft Tissue Sarcomas and Window Evaluation of Dose Rate on Gemcitabine Triphosphate Accumulation by PATEL, Shreyaskumar R, GANDHI, Varsha, JENKINS, Jan, PAPADOPOLOUS, Nicholas, BURGESS, M. Andrew, PLAGER, Carl, PLUNKETT, William, BENJAMIN, Robert S

“…To evaluate the efficacy, toxicity, and optimal dose rate of gemcitabine in adult patients with advanced soft tissue sarcomas (STS) by comparing levels of…”
Get full text

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma by Legha, S S, Ring, S, Eton, O, Bedikian, A, Buzaid, A C, Plager, C, Papadopoulos, N

“…To evaluate the antitumor activity and toxicity of concurrent biochemotherapy that uses cisplatin, vinblastine, and docarbazine (DTIC) (CVD) in combination…”
Get more information

Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system by Buzaid, A C, Ross, M I, Balch, C M, Soong, S, McCarthy, W H, Tinoco, L, Mansfield, P, Lee, J E, Bedikian, A, Eton, O, Plager, C, Papadopoulos, N, Legha, S S, Benjamin, R S

“…To critically review the accuracy of the current American Joint Committee on Cancer (AJCC) staging system for cutaneous melanoma and propose a more useful…”
Get more information

High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence by Patel, S R, Vadhan-Raj, S, Papadopolous, N, Plager, C, Burgess, M A, Hays, C, Benjamin, R S

“…To evaluate the efficacy and feasibility of high-dose ifosfamide (HDI) at a total dose of 14 g/m2 per cycle with mesna in combination with granulocyte…”
Get more information

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-α by Legha, S. S., Ring, S., Bedikian, A., Plager, C., Eton, O., Buzaid, A. C., Papadopoulos, N.

“…Background: Metastatic melanoma is commonly treated with chemotherapy and/or biological agents used separately. In this study we have investigated the efficacy…”
Get full text

Prognostic factors for survival of patients treated systemically for disseminated melanoma by Eton, O, Legha, S S, Moon, T E, Buzaid, A C, Papadopoulos, N E, Plager, C, Burgess, A M, Bedikian, A Y, Ring, S, Dong, Q, Glassman, A B, Balch, C M, Benjamin, R S

“…The current American Joint Commission on Cancer (AJCC) staging system distinguishes between soft tissue and visceral metastases in advanced (stage IV)…”
Get more information

Phase II evaluation of bryostatin-1 in metastatic melanoma by Bedikian, A Y, Plager, C, Stewart, J R, O'Brian, C A, Herdman, S K, Ross, M, Papadopoulos, N, Eton, O, Ellerhorst, J, Smith, T

“…In this phase II study we assessed the efficacy of bryostatin-1 (NSC 339555) in metastatic melanoma patients when given intravenously either once a week at a…”
Get full text

Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases by Buzaid, A C, Colome, M, Bedikian, A, Eton, O, Legha, S S, Papadopoulos, N, Plager, C, Ross, M, Lee, J E, Mansfield, P, Rice, J, Ring, S, Lee, J J, Strom, E, Benjamin, R

“…Our results with concurrent biochemotherapy in patients with stage IV melanoma have been encouraging. Based on these data, we conducted a phase II study to…”
Get more information

Recovery of sperm production after chemotherapy for osteosarcoma by Meistrich, M L, Chawla, S P, Da Cunha, M F, Johnson, S L, Plager, C, Papadopoulos, N E, Lipshultz, L I, Benjamin, R S

“…Because treatment with surgery and combination chemotherapy produces a high cure rate in young men with osteosarcoma, their subsequent reproductive function is…”
Get more information

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study by Lee, K H, Talpaz, M, Rothberg, J M, Murray, J L, Papadopoulos, N, Plager, C, Benjamin, R, Levitt, D, Gutterman, J

“…Twenty-seven patients with metastatic cancer were treated with a daily continuous intravenous (IV) infusion of recombinant human interleukin-2 (rhIL-2) along…”
Get more information

Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma by ETON, O, KHARKEVITCH, D. D, LEGHA, S. S, PLAGER, C, PAPADOPOULOS, N. E, BEDIKIAN, A. Y, BENJAMIN, R. S, BALCH, C. M, GIANAN, M. A, ROSS, M. I, ITOH, K, PRIDE, M. W, DONAWHO, C, BUZAID, A. C, MANSFIELD, P. F, LEE, J. E

“…Our objective was to determine the clinical activity, toxicity, and immunological effects of active immunotherapy using UVB-irradiated (UVR) autologous tumor…”
Get full text

Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma by Vadhan-Raj, S, Papadopoulos, N E, Burgess, M A, Linke, K A, Patel, S R, Hays, C, Arcenas, A, Plager, C, Kudelka, A P, Hittelman, W N

“…To evaluate the clinical safety and ability of PIXY321, a novel fusion protein of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF)…”
Get more information

Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic melanoma using two different schedules by Legha, S S, Papadopoulos, N E, Plager, C, Ring, S, Chawla, S P, Evans, L M, Benjamin, R S

“…Based on the reports of activity of interferons against metastatic melanomas, we conducted a phase II study of recombinant interferon alfa-2a (Roferon-A,…”
Get more information

Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results From a Phase III Randomized Trial by ETON, Omar, LEGHA, Sewa S, FENG ZHAN, BENJAMIN, Robert S, BEDIKIAN, Agop Y, LEE, J. Jack, BUZAID, Antonio C, HODGES, Cynthia, RING, Sigrid E, PAPADOPOULOS, Nicholas E, PLAGER, Carl, EAST, Mary Jo

“…The addition of cytokines to chemotherapy has produced encouraging results in advanced melanoma. In this phase III trial, we compared the effects of…”
Get full text

Osteosarcoma chemotherapy effect: a prognostic factor by Raymond, A K, Chawla, S P, Carrasco, C H, Ayala, A G, Fanning, C V, Grice, B, Armen, T, Plager, C, Papadopoulos, N E, Edeiken, J

“…Chemotherapy has become a routine part of the treatment of osteosarcoma. However, the precise role of preoperative chemotherapy remains in question. Between…”
Get more information

Clinical Parameters Related to Optimal Tumor Localization of Indium-111-Labeled Mouse Antimelanoma Monoclonal Antibody ZME-018 by Murray, James L, Rosenblum, Michael G, Lamki, Lamk, Glenn, Howard J, Krizan, Zdenko, Hersh, Evan M, Plager, Carl E, Bartholomew, Richard M, Unger, Michael W, Carlo, Dennis J

“…Radioimmunolocalization of an 111In-labeled mouse antimelanoma monoclonal antibody (MoAb), ZME-018, was examined in 21 patients with metastatic malignant…”
Get full text

Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy by Anderson, C M, Buzaid, A C, Sussman, J, Lee, J J, Ali-Osman, F, Braunschweiger, P G, Plager, C, Bedikian, A, Papadopoulos, N, Eton, O, Legha, S S, Grimm, E A

“…The combination of cisplatin-based chemotherapy with interleukin-2 (IL-2) and interferon-alpha (IFN-alpha), referred to as biochemotherapy, has produced…”
Get more information

The CLEO-III trigger: axial and stereo tracking by Hans, R.M., Plager, C.L., Selen, M.A., Haney, M.J.

“…The tracking subsystem of the CLEO-III Trigger consists of separate axial and stereo tracking pattern-matching modules, whose products are time-aligned and…”
Get full text

Myxoid malignant fibrous histiocytoma: experience with chemotherapy by Patel, S R, Plager, C, Papadopoulos, N E, Benjamin, R S

“…Myxoid malignant fibrous histiocytoma (MFH) is an intermediate grade tumor with a definite metastatic potential but a relatively indolent natural history…”
Get more information

DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma by Buzaid, A C, Ali-Osman, F, Akande, N, Grimm, E A, Lee, J J, Bedikian, A, Eton, O, Papadopoulos, N, Plager, C, Legha, S S, Benjamin, R S

“…The combination of cisplatin-based chemotherapy with interleukin-2 (IL-2) and interferon, referred to as biochemotherapy, has shown encouraging results in…”
Get more information